Silencing Notch1 signaling or HIF-1α inhibition showed a notable anti-growth effect in early treatment with doxycycline or chetomin, indicating that HIF-1α might be a promising therapeutic target even in an early stage of tumor progression. This evidence concerns the gene HIF1A and neoplasm.